Skip to main content
. Author manuscript; available in PMC: 2020 Aug 28.
Published in final edited form as: Immunopharmacol Immunotoxicol. 2019 May 7;41(3):428–437. doi: 10.1080/08923973.2019.1609026

Fig 3:

Fig 3:

a) Total cell count in BAL from study groups control (CON), allergen sensitized (SEN), allergen sensitized+ AT1 antagonist losartan (SEN+LOS), allergen sensitized+AT2 agonist novokinin (SEN+NOV) and allergen sensitized+AT2 antagonist PD 123319 (SEN+PD) groups. Losartan and novokinin reduced post-allergen inhalation mediated increase in total lung cell infiltrate, while PD 123319 had no effect. Values are described as mean±SEM, *p<0.05 compared to CON; #p<0.05 compared to SEN; †p<0.05 compared to SEN+LOS; ‡p<0.05 compared to SEN+NOV; n=4–12 Fig 3 b) Eosinophils c) Macrophages d) Neutrophils from BAL in control (CON), allergen sensitized (SEN), allergen sensitized+ AT1 antagonist losartan (SEN+LOS), allergen sensitized+AT2 agonist novokinin (SEN+NOV) and allergen sensitized+AT2 antagonist PD 123319 (SEN+PD) groups. Eosinophilia and neutrophilia were significantly reduced in allergic mice treated with losartan (SEN+LOS) and novokinin (SEN+NOV) compared to non-treated SEN. PD 123319 had no effect in allergic mice. With respect to macrophages, both losartan and novokinin lowered the attenuation of macrophages in treated allergic mice (SEN+LOS, SEN+NOV), while PD had no effect. Values are described as mean±SEM, *p<0.05 compared to CON; #p<0.05 compared to SEN; †p<0.05 compared to SEN+LOS; ‡p<0.05 compared to SEN+NOV; n=4–12